Precision Medicine for mNETs: Update on Organoid Research



Terence P. Gade MD PhD

Departments of Radiology and Cancer Biology Perelman School of Medicine, University of Pennsylvania 9th Annual Focus on Neuroendocrine Tumor 6 March 2020


DISCLOSURES

- Trisalus Life Sciences- Scientific Advisory Board
- Grant Funding
 - NIH
 - Veterans Administration
 - Society of Interventional Oncology
 - Society of Interventional Radiology
 - RSNA




NETS: A GROWING HEALTH PROBLEM

Increasing Incidence of NET



Metastatic Disease is Common






THERAPEUTIC TARGETING OF MNETS: CHALLENGES





Penn mNET Biopsy Protocol





Model Generation: Organoids

Tumor Organoids Provide Unique Cancer Models


- Self-organizing 3D structures grown *in vitro*
- Recapitulate the architecture and function of the parent human tumor
- Diverse applications
 - Study of representative cancer biology
 - Precision medicine
 - Identify optimal therapy for each patient



Schematic of Tumor Organoid




MNET ORGANOID CREATION: CHALLENGES





MNET ORGANOID CREATION: PROGRESS Optimized Culture Conditions



PRECISION MEDICINE

Personalized therapy against specific vulnerabilities in each patient's cancer

Key Components


- Consistent acquisition of tissue samples
- Safety & compatibility with current clinical workflow
- Robust patient-derived models (organoids)



The right drug for the right patient



PARADIGM



Precision Medicine: Patients 17 & 20

44 Hits that overlap

Class Catalog No. Targets

ATPase


lonCh \$1478

Product Name


Oligomycin A

					Oligomycin A	IonCh S1478	ATPase		
					Gemcitabine GZD824	cancer S1714 kinase S7194	Autophagy,DNA/RNA Bcr-Abl	Synthesis	
	15 Hite unique	a to Dat	iont 17	111000	Dinaciclib (SC 2795	kinase \$2768		+ 20 /	120121
	15 Hitseuniqu	elura	aitean t t th	(101020		unique	T QA/FNA CHLSB	ent zu (M2842)
					Panobinostat (LBH589)	epigenetic \$1030	HDAC		
Biopsy	Product Name	Class 🗋	Catalog No.	Targets	■1 ^{Q824} (isinos Product Nam	e	💽 Class 📑	🔨 Catalog No	. 💌 Targets 🚽
	PHA-793887	kinase	S1487	CDK	^{midep} Deguelin			S8132	Akt
	Celecoxib	cancer	S1261	сох	Chetomin KPT-2276	\$7939 cancer \$2639	HIF LORSCH	\$7251	CRM1
+	PP121	kinase	S2622	DNA-PK,F	PD ⁰⁴⁹²⁹ Poziotinib (HN	V781-36B)		S7358	EGFR
	I-BET151 (GSK120151A)	epigenet	tic S2 780	Epigenet	ic P990 (Will Bresib (A	BBV-075)097	HSP (e.g. HSP90)	S8400	Epigenetic f
Cell isolation &	GW9508	cancer	S8014	GPR	74392 17-AAG (Tane		cancer	S1141	HSP (e.g. H
expansion	Atorvastatin Calcium	netabol	is \$2077	HMG-Co.	AvihulastinBMS-707035	cancer S1248	Microrun WerASDIN		Integrase
	BI-847325		\$7843	MEK	blasti BAY 1217389			\$8215	Kinesin
	Pimasertib (AS-703026)	kinase_	S1475	MEK	Cucurbitacin B Nocodazo	S8165 cancer S2775	Microtubule Associate		p97
Validation	Cephalomannine	other	S2408	Others	ptolide (PG490)	cancer \$1241 cancer \$3604	Microtubule Associate Others	ed,Autophagy	
	Elaiophylin	microbio	1051448	Others	Nanchangmycin	microbiol \$1450	Others		
					Monomethyl auristatin E (MMAE)	\$7721 \$8144	Others Others		
	Apigenin	metabol		P450 (e.g	5. Cofuginone	kinase \$1363	PDGFR,c-Kit,VEGFR		
	VS-5584 (SB2343)	8	S7016	PI3K	CUDC-907	kinase \$2759	PI3K,HDAC		
	EHop-016	kinase	\$7319	Rac	RC T226 (NVP-BGT226) N0905	kinase S2749 S2898	PI3K,mTOR PLK		
		Kindse			IVII.N2238	cancer S2180	Proteasome		
	Dasatinib Monohydrate		S7782	Src	Bortezomib (PS-341) rfilzomib (PR-171)	cancer S1013 Protease S2853	Proteasome Proteasome		
Screen	QNZ (EVP4593)	cancer	S4902	TNF-alph	rozomib (ONX 0912)	Protease \$2853 Protease \$7049	Proteasome		
			0.002		CEP-18770 (Delanzomib)	Protease \$1157	Proteasome		
	Patient 17M				Epoxomicin	\$7038	Proteasome		
					KX2-391 Camptothecin	kinase S2700 cancer S1288	Src Topoisomerase		
					SN-38	cancer \$4908	Topoisomerase		
					Idarubicin HCI	cancer \$1228	Topoisomerase		
					(S)-10-Hydroxycamptothecin	\$2423	Topoisomerase		
					NPI-2358 (Plinabulin)	cancer \$1176	VDA		
								Y	IAD
								Penr	IR LAD

Precision Medicine: Patients 17 & 20



Precision Medicine: Patients 17 & 20





SUMMARY

 Feasible to establish mNET organoid cultures from needle biopsy samples



Drug screening enables identification of existing,
FDA-approved drugs on a patient-by-patient basis

Foundation for precision medicine approach to mNET



FUTURE DIRECTIONS: DEVELOPMENT FOR CLINICAL IMPLEMENTATION

Optimize culture of, and validate, *in vitro* (organoid) & *in vivo* models



FUTURE DIRECTIONS: DEVELOPMENT FOR CLINICAL IMPLEMENTATION

Optimize culture of, and validate, *in vitro* (organoid) models

Leverage models for precision medicine paradigm for patients with mNETs



Acknowledgements

Patient Volunteers

PIGI Lab

Penn IR

Dan Ackerman

Kelley Weinfurtner

Michael Soulen

Greg Nadolski

Stephen Hunt

James Chen

Tony Secreto Josh Glover

HT Screening Core

Stem Cell & Xenograft Core Funding

Sara Cherry David Schultz





Philanthropy

Rick Mainwaring

